Gossamer Bio to Participate in Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will participate in the following investor conferences in November.

UBS Global Healthcare Conference
Date / Time:		November 10th
Format:		1x1’s
Location:		Palm Beach, FL

Guggenheim Securities Healthcare Innovation Conference
Date / Time:		November 11th, at 10:00 AM ET
Format:		Presentation & 1x1’s
Location:		Boston, MA
Webcast Link:		HERE

About Gossamer Bio

Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with pulmonary hypertension.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251107017321/en/

For Investors and Media

Bryan Giraudo, Chief Financial Officer & Chief Operating Officer

Gossamer Bio Investor Relations

ir@gossamerbio.com

Source: Gossamer Bio, Inc.